Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD36 monoclonal antibody
- Development stage
- Preclinical
- Lead developer
- ONA Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CD36 monoclonal antibody (also known as ONA-036) is a humanized monoclonal antibody targeting CD36 (platelet glycoprotein 4), a fatty acid translocase and scavenger receptor involved in lipid metabolism and cancer metastasis. Developed by Ona Therapeutics, the antibody is designed to block CD36-mediated fatty acid uptake, thereby inhibiting the metabolic reprogramming that supports metastasis-initiating cells and immunosuppressive cells in the tumor microenvironment. ONA-036 is being investigated in preclinical models for the treatment of advanced solid tumors (such as oral, ovarian, and colon cancers) and acute myeloid leukemia (AML).
- Other names
- Ona Thera Patent Anti-Cd36Ona Thera Patent Cd36anti-CD36 monoclonal antibodyanti-CD-36 monoclonal antibodyanti-CD 36 monoclonal antibodyhumanized anti-CD36 antibody
02
Targets
CD36 (CD36 antigen)
Beyond the preview
Go deeper on CD36 monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD36 monoclonal antibody.